BioSpace News Archive

Masimo announced that its management is scheduled to participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 4:15 p.m. Eastern Time.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021.

Co-Diagnostics, Inc. announced that its Logix Smart™ COVID-19 Test Kit was used by Italian researchers to confirm the presence of SARS-CoV-2, including mutated strains of the virus, in a community surveillance method of testing single-use waste, with the peer-reviewed results published in the journal Science of the Total Environment.

TearClear, a late clinical stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution, 0.005%.

The patent pertains to a specialized 3D x-ray filter, known as a 3D-Beam Modulation Filter, that is designed to tailor the shape of the IzoView x-ray beam to match the shape of the patient’s breast being scanned.

This technology is a peripherally restricted cannabinoid receptor 1 antagonist that has successfully completed preliminary pre-clinical and in vivo testing requirements, including demonstrating it does not cross the blood brain barrier.

Intrommune Therapeutics, Inc. announced the appointment of Stuart Loesch as its new Chief Commercial Officer.

Cogitativo announced today that it is appointing Paul Mango to the company’s board of directors and hiring Terry Gilliland, M.D., as Chief Science Officer.

Strata Oncology, Inc today announced results from validation studies demonstrating the reliable performance of the StrataNGS test were published in The Journal of Molecular Diagnostics.

Stuart Therapeutics, Inc. today announced that it has completed patient enrollment in its Phase 2 clinical trial to evaluate the efficacy of its drug candidate ST-100